3-tert-Butyl-4-hydroxyanisole (3-BHA), one of the widely used food
antioxidants, has been found to act as a potential obesogen by promoting adipogenesis in vitro and inducing white adipose tissue development in vivo. Whether 3-BHA-induced
visceral obesity was accompanied by a disruption of hepatic
lipid homeostasis in mammals remained unclear. In this study, we evaluated the effect of
3-BHA on the development of
nonalcoholic fatty liver disease (
NAFLD) in male C57BL/6J mice. After 18 weeks of
oral administration of 10 mg/kg
3-BHA, the mice fed with a high-fat diet (HFD) had higher hepatic
triglyceride concentrations (0.32 mg/mg
protein) and severer steatosis (1.57 for the
NAFLD score) than the control ones. The in vivo hepatic
lipid deposition disturbed by
3-BHA was transcriptionally regulated by the genes involved in
lipid uptake, de novo lipogenesis,
fatty acid oxidation, and
lipid export. The in vitro studies further confirmed that 24 h of exposure to 50 μM
3-BHA could induce intracellular
oleic acid (OA) uptake and
triglyceride accumulation (1.5-fold of the OA control) in HepG2 cells. Lipidomic analysis indicated the perturbation of
3-BHA in the levels of 30
lipid species related to
sphingolipids,
glycerophospholipids, and glycerolipids under HFD conditions. The findings herein first revealed the disruption effect of
3-BHA on hepatic
lipid homeostasis, thus exacerbating the development of HFD-induced
NAFLD.